{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:46:58Z","timestamp":1769208418923,"version":"3.49.0"},"reference-count":36,"publisher":"Cambridge University Press (CUP)","issue":"12","license":[{"start":{"date-parts":[[2015,1,2]],"date-time":"2015-01-02T00:00:00Z","timestamp":1420156800000},"content-version":"unspecified","delay-in-days":762,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infect Control Hosp Epidemiol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:sec id=\"S0195941700050554_abs1\"><jats:title>Objective.<\/jats:title><jats:p>To evaluate the cost-effectiveness of a dual strategy of tuberculin skin test (TST) and QuantiFERON-TB Gold (QFT-G) for screening of latent tuberculosis infection (LTBI) in healthcare workers (HCWs) and, as a secondary objective, to study relationships between TST results, QFT-G results, and sociodemographic factors.<\/jats:p><\/jats:sec><jats:sec id=\"S0195941700050554_abs2\"><jats:title>Design.<\/jats:title><jats:p>Cross-sectional prospective study.<\/jats:p><\/jats:sec><jats:sec id=\"S0195941700050554_abs3\"><jats:title>Setting.<\/jats:title><jats:p>University hospital in Madrid.<\/jats:p><\/jats:sec><jats:sec id=\"S0195941700050554_abs4\"><jats:title>Participants.<\/jats:title><jats:p>A total of 103 HCWs.<\/jats:p><\/jats:sec><jats:sec id=\"S0195941700050554_abs5\"><jats:title>Methods.<\/jats:title><jats:p>QFT-G was requested for all positive TST results; QFT-G results were compared with TST results, and their relationships with sociodemographic factors were analyzed. A cost-effectiveness analysis was conducted for the dual strategy (TST\/QFT-G) and for TST or QFT alone, taking into account the indication of and compliance with isoniazid, the risk of hepatotoxicity, and postexposure tuberculosis.<\/jats:p><\/jats:sec><jats:sec id=\"S0195941700050554_abs6\"><jats:title>Results.<\/jats:title><jats:p>Of all HCWs studied, 42.3% showed a positive result by QFT-G, and 49.5% had received bacille Calmette-Gu\u00e9rin (BCG) vaccination; no significant association was detected between BCG and QFT-G results. Increased TST was linked to higher positive QFT-G values (TST of 5\u20139.9 mm, 27.6%; TST of 15 mm or more, 56.5%; <jats:italic>P<\/jats:italic> = .03). The probability of positive QFT-G results was 1.04 times higher for each year of age (odds ratio, 1.04 [95% confidence interval, 1.01\u20131.09]; <jats:italic>P<\/jats:italic> = .0257). The incremental cost per active TB case prevented was lower for TST\/QFT-G than for the other strategies studied (\u20ac14,211 per 1,000 HCWs). The number of people treated for LTBI per case of active TB prevented (number needed to treat) for TST\/QFT-G was lower than for TST alone (17.2 vs 95.3 and 88.7 with the 5- and 10-mm cutoff value, respectively) or QFT-G alone (69.6).<\/jats:p><\/jats:sec><jats:sec id=\"S0195941700050554_abs7\"><jats:title>Conclusions.<\/jats:title><jats:p>Dual strategy with TST\/QFT-G is more cost-effective than TST or QFT-G alone for the diagnosis of LTBI in HCWs.<\/jats:p><\/jats:sec>","DOI":"10.1086\/668436","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T21:41:05Z","timestamp":1351201265000},"page":"1226-1234","source":"Crossref","is-referenced-by-count":15,"title":["Cost-Effectiveness of Different Screening Strategies (Single or Dual) for the Diagnosis of Tuberculosis Infection in Healthcare Workers"],"prefix":"10.1017","volume":"33","author":[{"given":"M. Teresa","family":"del Campo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadia","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Marcela","family":"Sol\u00eds-Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Angeles","family":"S\u00e1nchez-Uriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Mah\u00edllo-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2015,1,2]]},"reference":[{"key":"S0195941700050554_ref003","unstructured":"Cellestis. Clinical Experience with QuantiFERON\u00ae-TB Gold (In-Tube). http:\/\/www.cellestis.com\/IRM\/Company\/ShowPage.aspx?CPID=1254. Published November 2001. Accessed December 3, 2011."},{"key":"S0195941700050554_ref034","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-009-9182-2"},{"key":"S0195941700050554_ref020","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","author":"Smieja","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"S0195941700050554_ref002","doi-asserted-by":"publisher","DOI":"10.1086\/502343"},{"key":"S0195941700050554_ref028","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.01.002"},{"key":"S0195941700050554_ref021","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2009.11.023"},{"key":"S0195941700050554_ref015","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2728"},{"key":"S0195941700050554_ref007","first-page":"297.e1","article-title":"Documento de consenso sobre diagn\u00f3stico, tratamiento y prevenci\u00f3n de la tuberculosis","volume":"28","author":"Gonz\u00e1lez","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"S0195941700050554_ref029","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.10.0344"},{"key":"S0195941700050554_ref032","unstructured":"Servicio de Epidemiolog\u00eda, Servicio Madrile\u00f1o de Salud de la Comunidad de Madrid. Registro Regional de Casos de Tuberculosis en la Comunidad de Madrid: Informe del A\u00f1o 2009. http:\/\/www.madrid.org\/cs\/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-disposition&blobheadername2=cadena&blobheadervalue1=filename%3DInforme+Regional+TB+2009.pdf&blobheadervalue2=language%3Des%26site%3DPortalSalud&blobkey=id&blobtable=MungoBlobs&blobwhere=1272102879448&ssbinary=true. Accessed January 9, 2012."},{"key":"S0195941700050554_ref001","first-page":"1","article-title":"Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005","volume":"54","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"S0195941700050554_ref035","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-11-247"},{"key":"S0195941700050554_ref033","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.524"},{"key":"S0195941700050554_ref004","first-page":"14","article-title":"Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers","volume":"29","author":"Girardi","year":"2009","journal-title":"Euro Surveill"},{"key":"S0195941700050554_ref010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1183\/09031936.06.00011806","article-title":"Cost-optimisation of screening for latent tuberculosis in close contacts","volume":"28","author":"Diel","year":"2006","journal-title":"Eur Respir J"},{"key":"S0195941700050554_ref005","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"S0195941700050554_ref017","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00016906"},{"key":"S0195941700050554_ref006","unstructured":"National Institute for Health and Clinical Excellence. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. http:\/\/www.nice.org.uk\/nicemedia\/live\/13422\/53642\/53642.pdf. Published March 2011. Accessed January 9, 2012."},{"key":"S0195941700050554_ref008","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.14.1760"},{"key":"S0195941700050554_ref011","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.12.4.491-496.2005"},{"key":"S0195941700050554_ref012","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1128\/CDLI.12.11.1311-1316.2005","article-title":"Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorben assay and an enzyme-linked immunospot assay","volume":"12","author":"Goletti","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"S0195941700050554_ref013","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68579-6"},{"key":"S0195941700050554_ref014","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.6.968"},{"key":"S0195941700050554_ref016","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.3.9902005"},{"key":"S0195941700050554_ref018","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.5.1184"},{"key":"S0195941700050554_ref019","first-page":"S127","article-title":"The cost-effectiveness of screening for latent tuberculosis infection","volume":"4","author":"Taylor","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"S0195941700050554_ref036","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2011-100068"},{"key":"S0195941700050554_ref022","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2009.09.004"},{"key":"S0195941700050554_ref023","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.22.2746"},{"key":"S0195941700050554_ref024","first-page":"513","article-title":"Prevalence and risk factors for latent tuberculosis infection among health care workers in Georgia","volume":"12","author":"Mirtskulava","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"S0195941700050554_ref026","first-page":"406","article-title":"Screening of latent tuberculosis infection in healthcare workers by Quantiferon TBG and tuberculin skin test","volume":"29","author":"Ciaschetti","year":"2007","journal-title":"G Ital Med Lav Ergon"},{"key":"S0195941700050554_ref025","doi-asserted-by":"publisher","DOI":"10.1086\/504358"},{"key":"S0195941700050554_ref027","first-page":"593","article-title":"Risk of tuberculosis infection and disease associated with work in healthcare setting","volume":"11","author":"Menzies","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"S0195941700050554_ref030","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-10-7"},{"key":"S0195941700050554_ref031","first-page":"16","article-title":"Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis","volume":"11","author":"Oxlade","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"S0195941700050554_ref009","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200505-748OC"}],"container-title":["Infection Control &amp; Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0195941700050554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T05:25:16Z","timestamp":1601270716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0195941700050554\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0195941700050554"],"URL":"https:\/\/doi.org\/10.1086\/668436","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}